On Monday, Moderna Inc. claimed that its Omicron-compliant vaccines improved the immune response against the BA.4/5 sub-variant. When administered as a booster dose, compared to its initial shot. The company found this in a mid-to-late stage study.
Data shows that in adults who were vaccinated and given booster shots, Moderna’s Omicron-analogous vaccines, mRNA-1273.214 and mRNA-1273.222, both protected against the BA.4/5 subvariant compared to their parent vaccine Generated a high antibody response.
In an analysis of nearly 40 participants, Moderna claimed that the level of neutralizing antibody response to the emerging subtype BQ.1.1 decreased by about 5-fold compared to BA.4/5, regardless of the virus neutralization rate. activity still remains “strong”. ,
Moderna’s Competitors Pfizer Inc. and its German partner BioNTech SEpreviously reported that after one month, their Omicron-tailored shot, which targets the BA.4/5 subvariants, generated a stronger antibody response than the original shot in older adults.
Omicron-compliant shots It has already received US approval for both adults and children under the age of five, based on data from pre-clinical studies conducted by Moderna and Pfizer. According to government data, as of November 9, about 31.4 million Americans had received the updated vaccine, with about 5.1 million receiving it just the previous week.
(with inputs from Reuters)
catch all business News, market news, today’s fresh news events and breaking news Updates on Live Mint. download mint news app To get daily market updates.